---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-137754"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:19:58.150013+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# IO Biotech Q1 2024 net loss $19.5M; Phase 3 melanoma interim ORR data expected Q3 2024

## Summary
- Net loss $19.5M for Q1 2024 vs $17.0M in Q1 2023; R&D expenses $14.3M (up from $11.9M).
- Cash and cash equivalents $118.0M at March 31, 2024; cash runway expected into Q4 2025.
- Phase 3 trial (IOB-013) of IO102-IO103 in advanced melanoma: interim ORR analysis expected Q3 2024; PFS analysis projected H1 2025.
- Completed Phase 2 basket trial (IOB-022) enrollment; Phase 2 basket trial (IOB-032) expanded with randomized melanoma cohort.
- Appointed Faiçal Miyara as Chief Business Officer and Marjan Shamsaei as SVP Commercial & Portfolio Lead.

## SEC filing metadata
- accession: 0001193125-24-137754
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312524137754/0001193125-24-137754-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312524137754/d799934d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-137754
- JSON: https://secwatch.observer/filing/0001193125-24-137754.json
- Plain text: https://secwatch.observer/filing/0001193125-24-137754.txt

## Key facts
- Earnings Releases
  IO Biotech, Inc. reported the first quarter ended March 31, 2024 results: net income $19.5 million.
  - Period: the first quarter ended March 31, 2024
  - Net income: $19.5 million
  - Result: reported results
  source text: Net loss for the three months ended March 31, 2024, was $19.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312524137754/0001193125-24-137754-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.